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Abstract
Magnesium reduces vascular smooth muscle cell (VSMC) calcification in vitro but the mechanism has not been revealed so
far. This work used only slightly increased magnesium levels and aimed at determining: a) whether inhibition of magnesium
transport into the cell influences VSMC calcification, b) whether Wnt/b-catenin signaling, a key mediator of osteogenic
differentiation, is modified by magnesium and c) whether magnesium can influence already established vascular
calcification. Human VSMC incubated with high phosphate (3.3 mM) and moderately elevated magnesium (1.4 mM)
significantly reduced VSMC calcification and expression of the osteogenic transcription factors Cbfa-1 and osterix, and up-
regulated expression of the natural calcification inhibitors matrix Gla protein (MGP) and osteoprotegerin (OPG). The
protective effects of magnesium on calcification and expression of osteogenic markers were no longer observed in VSMC
cultured with an inhibitor of cellular magnesium transport (2-aminoethoxy-diphenylborate [2-APB]). High phosphate
induced activation of Wnt/b-catenin pathway as demonstrated by the translocation of b-catenin into the nucleus, increased
expression of the frizzled-3 gene, and downregulation of Dkk-1 gene, a specific antagonist of the Wnt/b-catenin signaling
pathway. The addition of magnesium however inhibited phosphate-induced activation of Wnt/b-catenin signaling pathway.
Furthermore, TRPM7 silencing using siRNA resulted in activation of Wnt/b-catenin signaling pathway. Additional
experiments were performed to test the ability of magnesium to halt the progression of already established VSMC
calcification in vitro. The delayed addition of magnesium decreased calcium content, down-regulated Cbfa-1 and osterix
and up-regulated MGP and OPG, when compared with a control group. This effect was not observed when 2-APB was
added. In conclusion, magnesium transport through the cell membrane is important to inhibit VSMC calcification in vitro.
Inhibition of Wnt/b-catenin by magnesium is one potential intracellular mechanism by which this anti-calcifying effect is
achieved.
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Introduction
Clinical observations in uremic patients show that high
phosphate is associated with an increase in mortality [1–4].
Results obtained from experimental work demonstrate that high
serum phosphate is a critical factor in the development of vascular
calcification [3,5]. Thus phosphate binders that help to control
serum phosphate are commonly used in uremic patients [6–8].
Clinical studies indicate that magnesium-containing phosphate
binders are effective in controlling serum phosphate [9–12], and
their phosphate lowering properties have been described as either
resulting in or being associated with a decrease in vascular
calcification [13,14].
Dialysis patients tend to have increased concentrations of serum
magnesium and those patients receiving magnesium-containing
phosphate binders show a further elevation that is moderate but
significant, albeit not associated with any clinical symptoms [9].
The control of serum phosphate achieved with the use of
magnesium-based phosphate binders should benefit vascular
calcification; however, the impact of a moderate increase in
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serum magnesium on vascular calcification is not clear and
therefore deserves attention. Experimental studies suggest that a
high concentration of magnesium (2 to 3 mM) may prevent
calcification in vitro [15–18]; In addition, an interventional animal
study revealed reduced vascular calcification upon magnesium-
containing phosphate binder treatment [19]. However, the
magnesium concentrations used in these studies were much higher
than the serum magnesium levels found in patients treated with
magnesium-containing phosphate binders (1.360.3 mM or
1.060.1 mM) [9,20].
The mechanisms by which magnesium may influence vascular
calcification are unclear. It is known that in vitro, magnesium
impairs hydroxyapatite crystal growth [21]. A recent work [17]
demonstrated that inhibition of magnesium channels in VSMC
cultured with high phosphate and magnesium results in changed
expression of osteogenic genes. However, the influence of cellular
magnesium transport on vascular calcification at slightly elevated
concentrations and the mechanisms involved remain to be
elucidated.
Wnt signaling, which is essential for the osteogenic commitment
of pluripotent mesenchymal cells, has also been shown to be
activated during the development of vascular calcification in vivo
and in vitro [22–27]. Wnt proteins are a large family of secreted
molecules that signal through binding to a co-receptor complex
formed by proteins of the frizzled family and the lipoprotein
receptor-related 5/6 proteins. The activation of the canonical Wnt
pathway results in the nuclear translocation of b-catenin and
subsequent regulation of target gene expression [27].
The present study using only slightly elevated magnesium
concentrations was performed to determine, a) whether magne-
sium transport into the cell has any influence on VSMC
calcification b) whether magnesium modifies Wnt/b-catenin




Human aortic smooth muscle cells (VSMC) were obtained from
Clonetics (Lonza Walkersville, Inc., USA). Cells were cultured in
DMEM supplemented with FBS (20%) (Bio Whittaker; Verviers,
Belgium), Na pyruvate (1 mM), glutamine (4.5 g/L), penicillin
(100 U/mL), streptomycin (100 mg/mL), and HEPES (20 mM)
(all reagents from Sigma Aldrich Inc; MO, USA) at 37uC in a
humidified atmosphere with 5% CO2. Cells were used after the
5th passage.
Experimental design
In the control groups VSMC were cultured with standard
magnesium concentration (0.8 mM) and phosphate concentration
(0.9 mM). In the high phosphate groups, cells were incubated with
medium described above supplemented with phosphate salts:
Na2HPO4 and NaH2PO4 in 1:2 proportion (Sigma Aldrich Inc;
MO, USA), to reach a final concentration of 3.3 mM phosphate.
In the high magnesium groups MgCl2 was added to the high
phosphate medium to reach a final concentration of 1.4 or
2.6 mM. Three assays were performed with VSMC: a) to confirm
the effect of magnesium on VSMC calcification (9 days culture
with the same magnesium level), b) to study early expression of
genes implicated in Wnt/b-catenin signaling pathway (24 hours in
culture) and c) to reverse VSMC calcification (adding magnesium
at the 5th day of culture in calcifying conditions).
TRPM7 inhibition by 2-APB
Transient Receptor Potential Melastin 7 (TRPM7) was
inhibited in VSMC by incubation with 10 mM of 2-ami-
noethoxy-diphenylborate (2-APB, Sigma-Aldrich Inc; MO, USA).
Quantification of calcification
After the incubation period, cells were decalcified by 24 h
incubation in HCl (0.6 M). The calcium content in the superna-
tant was determined by the phenolsulphonephthalein method
(QuantiChromTM Calcium Assay Kit, BioAssay Systems, CA,
USA). Cells were washed 3 times with PBS (Sigma Aldrich Inc;
MO, USA) and solubilized in 0.1 M NaOH/0.1% SDS. Cell
protein content was measured by Bio-Rad protein assay (Bio-Rad
Laboratories GmbH, Munich, Germany). The calcium content
was normalized for total protein.
Real-Time polymerase chain reaction (RT-PCR)
Total RNA was isolated from VSMC using a RNA extraction
kit (RneasyTM, Qiagen, USA). cDNA was synthesized with a first
strand cDNA synthesis kit (Roche; IN, USA) from 0.5 mg of total
RNA. The primers used for PCR amplification are shown in
Table 1. Real-time PCR was performed in duplicate with
QuantiTect SYBR Green PCR (Qiagen; USA) according to the
manufacturer’s protocol. All PCR amplifications were carried out
using Lightcycler (Roche Molecular Biochemicals; IN, USA.). The
expression of target genes was normalized to the expression of b-
actin. All primers used were equally efficient.
Confocal microscopy
VSMC were seeded on coverslips, and after reaching 90%
confluence, they received the different treatments for 24 h. Then,
they were rinsed in PBS, fixed and permeated in cold 50%
methanol for 2 min, cold 100% methanol for 20 min, and cold
50% methanol for 2 min. The specimens were subsequently
Table 1. Primers used for quantitative RT-PCR analyses.
Cbfa-1 Fw 59-GCA GTT CCC AAG CAT TTC AT-39
Rv 59-CGG ACA TAC CGA GGG ACA T-39
Osterix Fw 59-ATC TGC CTG CGT CCT TGG GAC CCG-39
Rv 59-TGC TTT GCC CAG AGT TGT TGA GTC-39
MGP Fw 59-CCT GAA GTA GCG ATT ATA GGC-39
Rv 59-CCT GAA GTA GCG ATT ATA GGC-39
OPG Fw 59-CTT CAG GTT TGC TGT TCC TAC-39
Rv 59-CAG AGG TCA ATA TCT TGG ATG-39
Frizzled 3 Fw 59-TGG AGC CAT TCC ACC CTA TG-39
Rv 59-GAA CCT ACT GCA TTC CAT ATC-39
VCAN/versican Fw 59-ATA CGT GCA AGA AAG GAA CAG TCG-39
Rv 59-GTC CTT TGG TAT GCA GAT GGG TTC-39
Cyclin D1 Fw 59-CCG AGG AGC TGC TGC AAA TGG A-39
Rv 59-ATG GAG GGC GGA TTG GAA ATG AAC-39
c-Myc Fw 59-ACC ACC AGC AGC GAC TCT GAG GA-39
Rv 59-CGT AGT TGT GCT GAT GTG TGG AGA-39
DKK-1 Fw 59-ATA TTC CAG CGT TGT TAC TGT-39
Rv 59-CCA CAC TGA GAA TTT ACA ATA C-39
b-actin Fw 59-GCA CTC TTC CAG CCT TCC TT-39
Rv 59-ATC CAC ATC TGC TGG AAG GT-39
doi:10.1371/journal.pone.0089525.t001
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washed in PBS (365 min) and incubated for 1 h with anti-b-
catenin antibody (1:50; BD Pharmigen, NJ, USA) in blocking
solution (1% BSA) at room temperature. After being washed with
PBS (365 min), specimens were incubated for 1 h with Alexa
Fluor 488 F(ab’)2 fragment of rabbit anti-mouse IgG (1:5000;
Invitrogen, Paisley, UK) in PBS containing 1% BSA. After a final
wash with PBS (365 min), the specimens were counterstained with
DAPI for nuclear stain. Cells were mounted on slides to examine
fluorescence using a LSM 5 Exciter Carl Zeiss confocal
microscope. ImageJ software (National Institute of Health, USA)
was used to analyze confocal immunofluorescence staining.
Mander’s coefficient M2 plugin (DAPI vs. green) was used to
analyze nuclear translocation of b-catenin. Mander’s coefficient
M2 is the percentage of above-background pixels in blue color
(DAPI) that overlap above-background pixels in green color (b-
catenin).
siRNA knockdown of TRPM7 expression
A small interfering RNA (siRNA) was generated against
TRPM7. siRNA for knocking down TRPM7 was synthesized by
Qiagen (USA). The DNA target sequence of the annealed double
strand siRNA that we used was: 59-CCT GTA AGA TCT ATC
GTT CAA-39. siRNA, with a nonsilencing oligonucleotide
sequence (nonsilencing siRNA) that does not recognize any known
homology to mammalian genes, was also generated as a negative
control.
Cells (VSMCs) were seeded at a density of 26105 cells/well in
6-well plates and grown in DMEM containing 15% FBS and
antibiotics. One day after seeding, cells were transfected with
siRNA using siRNA Reagent System (Santa Cruz Biotechnology
Inc, USA) according to the manufacturer’s instructions. Briefly,
siRNA (40 pmol) was mixed with transfection medium (100 mL) to
which transfection reagent (6 mL) plus transfection medium
(100 mL) was added. After mixing (45 minutes), the formulation
was added dropwise onto the cells. Control cells were exposed to
transfectant in the absence of siRNA. 18 hours after transfection,
media was changed to DMEM containing 15% FBS and
antibiotics. Cells were lysed after 24 hours, and gene silencing
was monitored at the mRNA level by RT-PCR.
Statistics
Data are expressed as mean6SE. The difference between
means from two different groups was evaluated by t-test; the
difference between means for three or more groups was assessed
by ANOVA followed by Bonferroni post hoc analysis. P values less
than 0.05 were considered significant. The analyses were
performed using SPSS 15.0.
Results
The effect of magnesium on vascular smooth muscle cell
calcification
Incubation of VSMC in a medium with high phosphate
(3.3 mM) and physiological magnesium (0.8 mM) concentrations
produced calcification when compared to controls (p,0.001)
(Figure 1A). The addition of magnesium to the medium up to
1.4 mM caused a significant (p,0.001) reduction in calcification.
With a magnesium concentration of 2.6 mM, calcium content was
reduced further, which was similar to the amount of calcium found
in the control group.
Gene expression of the central osteogenic transcription factor
Cbfa-1 as well as its downstream effector osterix was significantly
increased in VSMC incubated with high phosphate medium vs.
controls (Figures 1B and 1C). The expression of Cbfa-1 and osterix
was reduced to control levels by the addition of magnesium to
1.4 mM. No further reduction in gene expression of osteogenic
transcription factors was detected when magnesium concentration
was increased to 2.6 mM.
Effect of inhibition of cellular magnesium receptor
(TRPM7) on VSMC calcification and osteogenic gene
expression
After having demonstrated the protective effect of magnesium
on VSMC calcification, further experiments were performed, and
the effect of 2-APB addition, an inhibitor of the magnesium
receptor TRPM7, was investigated. As shown in Figure 2A, the
protective effect of magnesium was abolished: Despite a magne-
sium concentration of 1.4 mM, the addition of 10 mM 2-APB
increased calcification to the same level as observed with a
magnesium concentration of 0.8 mM (p,0.001) (Figure 2A).
The increase in calcification observed with 10 mM 2-APB was
accompanied by an intensification of Cbfa-1 gene expression
(Figure 2B) as compared to VSMC incubated with the same
Figure 1. The effect of magnesium on calcification and
osteoblast-like transformation in VSMC in vitro. VSMC were
cultured with 3.3 mM P, and increasing concentrations of magnesium
(0.8 mM/1.4 mM/2.6 mM); control group with 0.9 mM P+0.8 mM Mg
was also included. (A), calcium content of VSMC cultured for 9 days.
Relative mRNA expression of Cbfa-1 (B) and osterix (C); a, P,0.001 vs
Control; b, P,0.001 vs VSMC with 3.3 mM P+0.8 mM Mg. Bars are the
mean6SE of three experiments in quadruplicate.
doi:10.1371/journal.pone.0089525.g001
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medium (3.3 mM phosphate/1.4 mM magnesium) but without 2-
APB (p,0.001).
To confirm the downstream effect the expression of matrix Gla
protein (MGP) (Figure 2C), a naturally occurring calcification
inhibitor [28], was investigated. It was increased (p,0.001) by the
high magnesium concentration (1.4 mM) despite the presence of
high phosphate, as compared to VSMC exposed to 3.3 mM
phosphate/0.8 mM magnesium. However, the addition of 10 mM
2-APB reduced MGP expression to the level obtained with a
magnesium concentration of 0.8 mM.
Low osteoprotegerin (OPG) has been associated with vascular
calcification [29]. A magnesium concentration of 1.4 mM doubled
OPG expression (Figure 2D) as compared with the 0.8 mM
magnesium condition. However, the addition of 10 mM 2-APB
prevented the increase in OPG level induced by magnesium (p,
0.005).
Magnesium inhibits phosphate-induced Wnt/b-catenin
signaling
The Wnt/b-catenin signaling pathway is known to be important
in phosphate-induced VSMC calcification (26), and its activation
results in nuclear translocation of b-catenin. The amount of
intracellular b-catenin was visualized by immunofluorescence
(Figure 3A). Cells cultured at normal phosphate and magnesium
concentrations showed nuclear exclusion of b-catenin whereas
cells cultured with high phosphate/normal magnesium concen-
trations presented a marked nuclear presence of b-catenin. An
increase in magnesium to 1.4 mM prevented nuclear translocation
of b-catenin. This effect was no longer observed after the addition
of 10 mM 2-APB which blocks magnesium’s entry via TRPM7.
Quantification of nuclear b-catenin staining intensity (see meth-
ods) confirmed the differences in the levels of nuclear b-catenin
fluorescence between groups (Figure 3B).
The expression of genes involved in Wnt/b-catenin signaling
pathway were also evaluated. Gene expression of frizzled 3
(Figure 4A), a receptor for Wnt ligands, was enhanced in VSMC
treated with high phosphate/normal magnesium as compared to
cells incubated with normal phosphate/normal magnesium.
Increasing the magnesium concentration to 1.4 mM decreased
the expression of frizzled 3 to values observed in cells incubated at
control conditions. The addition of 10 mM 2-APB reversed this
effect and frizzled 3 expression increased to a level also detected
under conditions with high phosphate/normal magnesium.
Dkk-1 (Dickkopf-related protein 1) is a specific natural
antagonist of the Wnt/b-catenin pathway. It non-significantly
decreased in VSMC cultured with high phosphate/normal
magnesium (Figure 4B), while VSMC incubated with high
phosphate/high magnesium showed a marked increase in Dkk-1
expression. The addition of 10 mM 2-APB reversed the effect of
high magnesium on Dkk-1 expression.
As additional direct Wnt/b-catenin transcription targets
VCAN/versican (a large chondroitin sulfate proteoglycan; a
member of the aggrecan/versican proteoglycan family.
Figure 4C), cyclin D1 (an early marker of cells entering the cell
cycle. Figure 4D) and c-Myc (a transcription factor which plays a
direct role on DNA replication. Figure 4E) were examined. High
Figure 2. Inhibition of TRPM7 abrogates protective effect of magnesium on calcification and gene expression on VSMC. VSMC were
cultured with 3.3 mM P+1.4 mM Mg with the TRPM7 inhibitor 2-APB (10 mM). VSMC with 3.3 mM P+0.8 mM Mg were also included. The graphics are
(A) calcium content, and the relative mRNA expression of (B) Cbfa-1, (C) MGP, and (D) OPG. a, P,0.05 vs VSMC with 3.3 mM P+0.8 mM Mg; b, P,
0.05 vs VSMC with 3.3 mM P+1.4 mM Mg. Bars are the mean6SE of three experiments in quadruplicate.
doi:10.1371/journal.pone.0089525.g002
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phosphate/normal magnesium medium enhanced the expression
of VCAN/versican, cyclin D1 and c-Myc, whereas 1.4 mM
magnesium significantly decreased the expression. This effect was
reversed by inhibition of magnesium transport using 2-APB.
Knock down of TRPM7 activates Wnt/b-catenin signaling
Treatment with 2-APB suggested that TRPM7 was involved in
the regulation of Wnt pathway by TRPM7 channels, however the
actions of 2-APB are not restricted to inhibition of TRPM7. To
confirm the specific role of TRPM7 in the regulation of canonical
Wnt signaling, human VSMC were transfected to knock down
TRPM7 expression.
TRPM7 mRNA expression was 50% reduced (p,0.001) in
VSMC transfected with siRNA vs. wild-type cells (Figure 5A).
Gene expression of frizzled 3 receptor was significantly (p,0.05)
increased on transfected VSMC (Figure 5B). Indeed, transfection
with TRPM7 siRNA enhanced expression of the direct Wnt/b-
catenin transcription target VCAN/versican (p,0.005; Figure 5C).
No differences were observed between transfected and not
transfected cells in DKK1 expression (Figure 5D).
Magnesium halts and decreases calcification in cultured
vascular smooth muscle cells
To investigate the effect of magnesium on already existing
calcification, human VSMC were incubated with high phosphate
and normal magnesium concentrations in the medium during a 5
day period and then switched to one of the following culture media
for an additional 4 days: a) medium with high phosphate and high
magnesium (1.4 mM), b) medium with high phosphate and high
magnesium supplemented with 10 mM 2-APB, and c) medium
with normal phosphate and normal magnesium; this last medium
served to compare the benefits of lowering phosphate concentra-
tion versus increasing magnesium concentration. Some cells were
maintained in high phosphate and normal magnesium until day 9.
In VSMC cultured at normal magnesium and high phosphate,
calcification progressively increased until the end of the experi-
ment at day 9 (Figure 6). The increase in magnesium from 0.8 to
1.4 mM at day 5 produced a subsequent decrease in calcification
(p,0.01). The addition of 10 mM of 2-APB to the high phosphate/
high magnesium media at day 5, produced no significant changes
in calcium content from day 5 to day 9.
Lowering phosphate to normal concentrations at day 5 resulted
in a significant decrease in calcification at day 9 (p,0.05). This
effect was similar to the one observed in the 3.3 mM phosphate/
1.4 mM magnesium group.
As shown in Figure 7A, the expression of Cbfa-1 was increased
at day 5 (p,0.001) in VSMC treated with high phosphate/normal
magnesium and remained elevated until day 9. Adding 1.4 mM
magnesium at day 5 significantly (p,0.01) decreased Cbfa-1
expression at day 9. Treatment with 10 mM 2-APB showed a
tendency (n.s.) to increase Cbfa-1 expression. Similar results were
observed when cells were switched to normal phosphate/normal
magnesium medium at day 5: Cbfa-1 expression was slightly
enhanced as compared to the 1.4 mM magnesium group (n.s.).
Figure 3. Magnesium inhibits b-catenin translocation into the nucleus in VSMC. VSMC cultured with 3.3 mM P, 3.3 mM P+1.4 mM Mg, and
3.3 mM P+1.4 mM Mg+10 mM 2-APB. Control group with 0.9 mM P+0.8 mM Mg was also included. Intracellular localization of b-catenin was
visualized by immunofluorescence using confocal microscopy. (A) For each group, b-catenin (green immunofluorescence) is shown left; in the middle
the same sample is counterstained with DAPI (blue) for nuclear stain; the merged image is shown right. Images represent four different experiments.
(B) Quantification of nuclear b-catenin staining was performed by the Mander’s coefficient (M2 plugin: DAPI vs. green). a, P,0.005 vs controls; b, P,
0.005 vs VSMC with 3.3 mM P+0.8 mM Mg; and c, P,0.05 vs VSMC with 3.3 mM P+1.4 mM Mg. Bars are the mean6SE of four experiments.
doi:10.1371/journal.pone.0089525.g003
Mg Inhibits Wnt/b-Catenin in VSMC
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In these experiments the expression of osterix (Figure 7B)
showed the same tendency as the Cbfa-1 expression, but
intergroup differences were not significant.
MGP expression (Figure 7C) was up-regulated by the addition
of magnesium at day 5 and 2-APB caused a down-regulation of
MGP. A reduction of phosphate concentration to 0.9 mM did not
produce any change in MGP expression.
Figure 4. Magnesium inactivates Wnt/b-catenin signaling pathway in VSMC. Relative mRNA expression on VSMC cultured with 3.3 mM P,
3.3 mM P+1.4 mM Mg, and 3.3 mM P+1.4 mM Mg+10 mM 2-APB. Control group with 0.9 mM P+0.8 mM Mg was also included. (A) Frizzled 3, (B)
DKK-1, (C) VCAN/versican, (D) cyclin D1, and (E) c-Myc. a, P,0.05 vs controls; b, P,0.05 vs VSMC with 3.3 mM P+0.8 mM Mg; and c, P,0.05 vs VSMC
with 3.3 mM P+1.4 mM Mg. Bars are the mean6SE of three experiments in triplicate.
doi:10.1371/journal.pone.0089525.g004
Figure 5. siRNA inhibition of TRPM7 activates Wnt/b-catenin signaling pathway in VSMC. Relative mRNA expression of VSMC transfected
with siRNA of TRPM7 24 hours after transfection, wild-type VSMC were included as controls. (A) TRPM7, (B) Frizzled 3, (C) VCAN/versican, (D) DKK-1.
a, P,0.05 vs controls. Bars are the mean6SE of two experiments in triplicate.
doi:10.1371/journal.pone.0089525.g005
Mg Inhibits Wnt/b-Catenin in VSMC
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Similar results were observed in OPG expression (Figure 7D): in
cells incubated at high phosphate, the increase in magnesium to
1.4 mM at day 5 produced a significant increase in OPG
expression by day 9. However, OPG expression was significantly
down-regulated by 2-APB. Lowering phosphate to normal levels
slightly increased OPG expression (n.s.).
Discussion
The present work confirms that magnesium reduces VSMC
calcification and osteogenic transdifferentiation even at only
slightly elevated, clinically relevant magnesium concentrations.
This effect is mediated through cellular magnesium transport as an
inhibition of the magnesium transporter TRPM7 results in the
abolition of the beneficial effects of magnesium on calcification
and prevention of osteogenic phenotype. Furthermore, this study
provides insights into intracellular mechanisms for the first time. It
shows that magnesium down-regulates the Wnt/b-catenin signal-
ing pathway which may explain its protective effect against VSMC
calcification. Interestingly, magnesium not only reduces calcifica-
tion of VSMC, but is also able to reverse this process after it has
been initiated. Taken together our findings demonstrate that
magnesium, even at moderately elevated concentrations, has an
active role in the prevention of phosphate-induced VSMC
calcification.
The present study used an in vitro model of VSMC calcification
that has been widely applied [30–33]. In this model the presence
of high phosphate produces osteogenic differentiation and
calcification of VSMC.
Recent in vitro studies have demonstrated the benefits of
magnesium on vascular calcification and provided important
Figure 6. Magnesium halts VSMC calcification induced by high
phosphate. VSMC calcification was induced with 3.3 mM P+0.8 mM
Mg for 5 days. At the 5th day, the medium was switched to 3.3 mM P+
1.4 mM Mg, 3.3 mM P+1.4 mM Mg+10 mM 2-APB or 0.9 mM P+0.8 mM
Mg and was maintained until day 9; a, P,0.01 vs 0 days; b, P,0.05 vs
VSMC with 3.3 mM P+0.8 mM Mg for 5 days; c, P,0.001 vs VSMC with
3.3 mM P+0.8 mM Mg for 9 days. Values are the mean6SE of four
experiments in quadruplicate.
doi:10.1371/journal.pone.0089525.g006
Figure 7. Magnesium halts Cbfa-1 expression and up-regulates MGP and OPG when added to VSMC with already existing
calcification. VSMC calcification was induced with 3.3 mM P+0.8 mM Mg for 5 days. At the 5th day, the medium was switched to 3.3 mM P+1.4 mM
Mg, 3.3 mM P+1.4 mM Mg+10 mM 2-APB or 0.9 mM P+0.8 mM Mg and was maintained until day 9. The graphics are the relative mRNA expression of
(A) Cbfa-1, (B) osterix, (C) MGP, and (D) OPG. a, P,0.05 vs VSMC with 3.3 mM P+0.8 mM Mg for 5 days 0 days; b, P,0.05 vs VSMC with 3.3 mM P+
0.8 mM Mg for 9 days; and c, P,0.01 vs VSMC with 3.3 mM P+1.4 mM Mg for 5 to 9 days. Values are the mean6SE of three experiments in triplicate.
doi:10.1371/journal.pone.0089525.g007
Mg Inhibits Wnt/b-Catenin in VSMC
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insights into magnesium’s role in regulating this process. Magne-
sium concentrations of 2 to 3 mM have been shown to reduce
calcification and osteogenic transformation of VSMC [15–18].
However, these magnesium concentrations are higher than the
values observed in patients taking magnesium-based phosphate
binders (1 to 1.4 mM) [9,11,20]. Our study used 1.4 mM
magnesium and was chosen to mimic a level closer to the one
observed in patients.
Our results show that 1.4 mM magnesium substantially
decreases calcification and osteogenic transdifferentiation in
VSMC incubated with high phosphate.
Furthermore, we found that the osteogenic transcription factors
Cbfa-1 and osterix are decreased while the expression of both
natural calcification inhibitors MGP and OPG are increased.
Down-regulation of Cbfa-1 and up-regulation of MGP by
magnesium has been previously described in VSMC [15,17] but
to our knowledge, the association between magnesium and osterix
as well as OPG in the context of VSMC calcification has not been
reported so far.
Osterix is a transcription factor influencing the maturation of
osteoblasts and has shown to be elevated in calcifying VSMC [34].
OPG is a protein which is expressed in normal VSMC and down-
regulated in calcified VSMC [29]. This protein protects the cells
against calcification by reducing alkaline phosphatase activity [35],
as well as by exerting an inhibitory effect on apoptosis [36]. This is
important as apoptotic bodies may act as nucleation sites for the
crystallization of apatite [37,38]. Moreover, a recent study showed
that magnesium at a concentration of 2–3 mM inhibits high
phosphate-induced apoptosis [15].
Despite these different investigations the mechanism(s) by which
magnesium reduces vascular calcifications are still not fully
elucidated. It has been shown that magnesium influences
calcium/phosphate (hydroxyapatite) crystallization [39]. Even at
low concentrations, magnesium ions have a marked effect on
nucleation and growth of calcium phosphates. These ions delay
the conversion of amorphous calcium precipitates to the more
stable apatite phase and promote the formation of whitlockite
[21,40–42]. Whitlockite is a calcium/magnesium orthophosphate
(Ca,Mg)3(PO4)2 that may produce less stress in VSMC than pure
hydroxyapatite crystals. In addition to this passive phenomenon,
these and other results also point to an active role of magnesium
and a direct effect on gene expression [16].
To test if the observed effect of magnesium in preventing
calcification requires active transport of magnesium into the cells,
VSMC were exposed to 2-APB, an inhibitor of TRPM7 which
regulates magnesium homeostasis in VSMC [17,43,44]. The
results of our experiments are uniform: an inhibition of
magnesium transport completely abolishes the beneficial effects
of magnesium on VSMC calcification. The central osteogenic
transcription factor Cbfa1 is upregulated in VSMC cultured with
high phosphate, magnesium and 2-APB, indicating that the
inhibitory effect of magnesium on phosphate-induced overexpres-
sion of this gene is no longer present. Furthermore, the preventive
effect of magnesium on the reduced gene expression of the
effectors MGP and OPG in VSMC under calcifying conditions is
abrogated in cultures exposed to the TRPM7 inhibitor. These
findings suggest that in addition to the above mentioned effects of
magnesium on crystal growth there seems to be an intracellular
effect of magnesium on the regulation of calcification and
osteoblast-like transformation. This effect depends on an active
entry of magnesium via TRPM7. As a unique characteristic the
‘‘chanzymes’’ TRPM7 and its homologue TRPM6 also possess an
intracellular alpha-kinase domain [44]. Its influence on the
transporter activity has been shown for TRPM6 [45] and
therefore might as well affect the processes observed here.
Wnt/b-catenin pathway has been implicated in the regulation
of phosphate-induced osteogenic transdifferentiation and calcifi-
cation in VSMC in vitro [25,27,46,47]. We show that in VSMC
cultured with high phosphate, magnesium prevents the transloca-
tion of b-catenin into the nucleus, and this effect is not observed if
transmembrane magnesium transport is abolished with the use of
2-APB. The inhibitory effect of magnesium on the cellular
signaling pathway is reflected by a reduced expression of frizzled
3, VCAN/versican, cyclin D1 and c-Myc and enhanced
expression of DKK-1. All this magnesium effects are reversed by
2-APB. The role of DKK1 in the inhibition of mineralization is
clearly stablished. In a previous publication of our group [27], we
have demonstrated that calcium deposition was significantly
reduced when DKK1 was added to VSMC cultured with high
phosphate.
Thus, our results show that high magnesium prevents the
phosphate-induced Wnt/b-catenin activation. For the first time,
this provides a possible mechanism by which magnesium reduces
calcification in VSMC under calcifying conditions.
2-APB is an inhibitor of TRP (Transient Receptor Potential)
receptor family [48,49] including TRPM7 [17], Thus 2-APB
inhibits the magnesium channel efficiently but it is not specific.
Additional studies were performed to knock down TRPM7
expression and determine the role of TRPM7 on the regulation
of Wnt/b-catenin signaling pathway. We found that the inhibition
of 50% of gene expression results in activation of Wnt/b-catenin
genes without producing any change in DKK1 expression. This
suggests that the partial inhibition of TRPM7 is not enough to
down-regulate DKK1, nevertheless, as we showed in results, the
presence of moderately elevated magnesium concentration can
significantly up-regulate this inhibitor of the Wnt pathway. Taken
together these data reinforce the importance of magnesium and
TRPM7 on regulation of Wnt/b-catenin signaling pathway.
Another novel and notable finding of the present work is the
reduction of calcification in VSMC treated with magnesium after
calcification has already been established. These experiments were
performed to investigate whether magnesium is able to stop the
progression of calcification. The results indicate that calcification is
not only halted but even decreased once magnesium is added. This
reversion of calcification is accompanied by significant changes in
gene expression of Cbfa-1, osterix, MGP and OPG which further
substantiates our results. Notably, the effect of adding magnesium
is at least as strong as the effect of reducing phosphate levels for all
parameters investigated.
An inhibition of the magnesium channel TRPM7 by 2-APB
results in the same calcification level found at the starting point (5
days). This is accompanied by a marked down-regulation of MGP
and OPG. Of note, Cbfa-1 and osterix are also partly down-
regulated. Taken together, the inhibition of magnesium entrance
into VSMC once calcification has been initiated does not
completely abrogate but reduces the protective effect of magne-
sium.
These results open new perspectives for the treatment of already
existing calcifications in patients and may imply that serum
magnesium levels above the upper limit of normal might be
beneficial in reducing vascular calcification. One could hypothe-
size that the administration of magnesium salts to renal patients
might be beneficial through two independent mechanisms: firstly,
the lowering of serum phosphate and secondly, a direct cellular
effect of magnesium. To confirm the clinical relevance of these
findings prospective, randomized, long-term clinical trials are
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needed to assess an independent role of magnesium on vascular
calcification.
In conclusion, even only slightly increased magnesium concen-
trations not only prevent, but also reverse VSMC calcification in
vitro. The effect of magnesium on VSMC calcification appears to
be a result of the inhibition of Wnt/b-catenin signaling pathway.
This novel finding provides an important insight into the cellular
mechanisms by which magnesium exerts its beneficial effect on
VSMC calcification.
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